Abstract
The plasma levels of hexobarbital in humans were determined during and after a 30-min or 60-min zero-order intravenous infusion. Hexobarbital kinetics could be described by conceiving the body to exhibit two compartments. The plasma concentrations were fitted to the postinfusion equation and the parameters intrinsic to the two- compartment open model were estimated. The elimination half-life varied considerably among the 14 individuals (160–441 min), which could mainly be explained by the greatly varying metabolic clearance of the compound (123–360 ml /min). The apparent volume of distribution per kilogram of body weight was relatively constant (1.10±0.12 liters/kg).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
M. T. Bush and W. L. Weller. Metabolic fate of hexobarbital.Drug Metab. Rev. 1: 249–290 (1972).
B. B. Brodie. Physiological disposition and chemical fate of thiobarbiturates in the body.Fed. Proc. 11: 632–639 (1952).
J. Sjögren, L. Solvell, and I. Karlsson. Studies on the absorption rate of barbiturates in man.Acta Med. Scand. 178: 553–559 (1965).
M. T. Bush, G. Berry, and A. Hume. Ultra-short-acting barbiturates as oral hypnotic agents in man.Clin. Pharmacol. Ther. 7: 373–378 (1966).
D. D. Breimer and J. M. van Rossum. Rapid and sensitive gas Chromatographic determination of hexobarbital in plasma of man using a nitrogen detector.J. Chromatog. 88: 235–243 (1974).
D. D. Breimer and J. M. van Rossum. Pharmacokinetics of (+)-, (−)- and (±)-hexobarbital in man after oral administration.J. Pharm. Pharmacol. 25: 762–764 (1973).
E. Richter, W. Zilly, D. Brachtel, and S. Becker. Zur Frage der Barbiturattoleranz bei Patienten mit akuter Hepatitis.Deutsch. Med. Wschr. 97: 254–255 (1972).
W. Zilly, D. Brachtel, and E. Richter. Hexobarbitalplasmaspiegel bei Patienten mit akuter Hepatitis während kontinuierlichter Hexobarbital-Infusion.Klin. Wschr. 51: 346–347 (1973).
W. Zilly, E. Richter, and D. D. Breimer. Pharmacokinetics of hexobarbital in patients with liver disease. In preparation.
H. L. Price and R. D. Dripps. Intravenous anesthetics. In L. S. Goodman and A. Gilman (eds.),The Pharmacological Basis of Therapeutics, 4th ed., Macmillan, New York, 1970, pp. 93–97.
S. Riegelman, J. C. K. Loo, and M. Rowland. Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.J. Pharm. Sci. 57: 117–123 (1968).
J. C. K. Loo and S. Riegelman. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.J. Pharm. Sci. 59: 53–55 (1970).
J. M. van Rossum. Significance of pharmacokinetics for drug design and the planning of dosage regimens. In E. J. Ariëns (ed.),Drug Design, Vol. I, Academic Press, New York, 1971, pp. 469–521.
M. Siegert, B. Alsleben, W. Liebenschütz, and H. Remmer. Unterschiede in der mikrosomalen Oxydation und Acetylierung von Arzneimitteln bei verschiedenen Arten und Rassen.Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol. 247: 509–521 (1964).
Author information
Authors and Affiliations
Additional information
This work was supported in part by a grant from the Netherlands Foundation for Medical Research FUNGO.
Rights and permissions
About this article
Cite this article
Breimer, D.D., Honhoff, C., Zilly, W. et al. Pharmacokinetics of hexobarbital in man after intravenous infusion. Journal of Pharmacokinetics and Biopharmaceutics 3, 1–11 (1975). https://doi.org/10.1007/BF01066591
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01066591